Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gilead's R&D Leadership Change Is End Of Bischofberger Era

Executive Summary

Norbert Bischofberger has been with Gilead almost since its beginning and helped the company establish dominance in HIV and hepatitis C, but leaves as it's starting to build franchises in oncology and inflammation. Gilead veterans John McHutchinson and Andrew Cheng are elevated in his place.


Related Content

Gilead Maintains Optimistic Outlook For Yescarta Despite Slow Growth
Pharma Q2 Results Preview: Lilly, Biogen, GSK And Gilead
Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV
Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground
Gilead Data Suggest Role For ACC Inhibition In NASH
What's Gilead Getting From Kite For Nearly $12bn?
Gilead Completes HCV Clinical Development With Vosevi Approval
Gilead Cites 'More Sophisticated' Process As Pressure For A Major Deal Increases
Pharmasset soars on $11B offer, but Gilead investors disturbed


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts